Molecular Design International, Inc.

Memphis, TN 38111

SBIR Award Summary

Total Number of Awards 25
Total Value of Awards $2.72MM
First Award Date 03/01/85
Most Recent Award Date 09/01/11

Key Personnel

Last Name Name Awards Contact
Parish Harlie A Parish 7
Robinson Charles N Robinson 1
Purcell William Paul Purcell 8
Miller Duane D Miller 1
Wainer Irving W Wainer 3
Feller Dennis Rudolph Feller 3
Clarke Robert R. Clarke 1
Steinle Jena J Steinle 1

25 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-10-051
Budget: 09/01/11 - 08/31/12

DESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal of non-proliferative diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness in working age adults. The current treatment para...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 04/01/09 - 03/31/10

DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Past studies from our...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 07/25/08 - 01/24/09

DESCRIPTION (provided by applicant): MDI-301 is a synthetic retinoid. MDI-301, like RA, induces collagen synthesis and reduces expression of collagen-degrading matrix metalloproteinases in the skin. This agent also induces epidermal thickening. However, unlike RA, MDI-301 is non-irritating when applied topically. In a recent study we showed that...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 04/17/08 - 03/31/09

DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Past studies from our...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/30/06 - 06/29/07

DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degrading enzymes in skin. A major feature that distinguishes MDI 301 from RA is its lack of irritation when applied topically to skin. Recent studies f...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/06 - 03/31/07

DESCRIPTION (provided by applicant): This application represents the Phase II version of SBIR grant R43 AR049621 entitled "Non-Irritating Retinoids for the Treatment of Aging Skin". Studies carried out prior to Phase I and during the Phase I portion of this project have demonstrated that a synthetic retinoid (identified as MDI-301) is as effecti...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/05 - 03/31/06

DESCRIPTION (provided by applicant): This application represents the Phase II version of SBIR grant R43 AR049621 entitled "Non-Irritating Retinoids for the Treatment of Aging Skin". Studies carried out prior to Phase I and during the Phase I portion of this project have demonstrated that a synthetic retinoid (identified as MDI-301) is as effecti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/03 - 08/31/04

DESCRIPTION (provided by applicant): Molecular Design International, Inc. (MDI) has designed and synthesized three synthetic retinoids based on the removal of the free carboxylic acid proton and replacement with an ester moiety in 14-all trans retinoic acid (RA), 13-cis retinoic acid (13-cis RA) and 9-cis retinoic acid (9-cis RA), respectivel...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 03/15/01 - 09/14/01

DESCRIPTION: (Applicant's description) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationships. Microliter plates with immobilized target receptors can rapidly reduce thousands of possibilities to hundreds of candida...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/99 - 06/30/00

DESCRIPTION: (Adapted from the applicant's abstract) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationships. Microtiter plates with immobilized target receptors can rapidly reduce thousands of possibilit...

Load More